Clinical Oncology Summit
Part 2: May 16, 2023 (Europe) | May 18, 2023 (North America)
A two-part virtual event to help clinical diagnostic labs learn how to improve your existing pipelines for somatic NGS analysis, interpretation and reporting
Scale and optimize your current pipeline
Join thought leaders, NGS experts, lab directors, variant scientists, clinicians, and oncologists under one virtual roof at the 2023 Clinical Oncology Summit hosted by QIAGEN Digital Insights. Designed to help clinical diagnostic labs understand how they can optimize their current pipelines for somatic NGS analysis, interpretation and reporting, the Clinical Oncology Summit is a must-attend event for labs who need to reduce turnaround time, improve operational costs, and scale for higher throughput.
Learn how to scale variant interpretation and reporting for QIAGEN QIAseq, PGDx, and llumina® TruSight Oncology 500 panels.
FEATURE
SUMMIT AGENDA
Part 2: Expert Panel Discussions
Tuesday, May 16, 2023 (Europe) and Thursday, May 18, 2023 (North America)
Join us for an expert panel of key opinion leaders, lab directors and molecular pathologists that will discuss the future of comprehensive genomic profiling. Two sessions are offered for Europe and North America attendees.
Europe Session | May 16, 2023
10:00 AM (CEST)
Speakers:
Laura Lahtinen, PhD
Molecular Biologist, Hospital Nova of Central Finland
Christoph Schmitt
Biologist, GenoPath Diagnostics
Miguel Angel Molina, PhD
Laboratory Scientific Director, PanOncology
Elif Dagdan, PhD
Ruhr University Bochum, RUB Department of General Internal Medicine
North America Session | May 18, 2023
1:00 PM (EDT)
Speakers:
Elizabeth Forrester, PhD, MB (ASCP)
Founder and Technical Director at Athena Esoterix
Sarah Murray, PhD, FACMG
Director, Medical Genetics and Genomics, UCSD Center for Advanced Laboratory Medicine
Kristen Champion, PhD, FACMG
Scientific Director, Molecular Oncology at Quest Diagnostics
Martina Lefterova, MD, PhD
Vice President and Clinical Laboratory Director at Guardant
Part 1: Educational Sessions (previously aired)
Now available on-demand
Part 1 of the 2023 Clinical Oncology Summit took place on April 27th. The first installment was an educational series providing information on the latest databases, software and services for clinical somatic NGS testing from QIAGEN Digital Insights. Two sessions were offered for Europe and North America attendees. Agenda information is below.
Europe Session
Learn about QIAGEN’s solution for cloud-based NGS secondary analysis and how to get started quickly with configurable pre-made workflows.
Speaker: Leif Schauser, PhD, Director, Global Product Management, QIAGEN Digital Insights
Learn how QIAGEN’s high-quality, deeply curated knowledge can help support and scale your variant interpretation. In addition, this talk will discuss the effects of co-occurring variants on prognosis and diagnosis and how to dentify evidence-based therapy options for cancer patients for whom there is no on-label therapy.
Speaker: Kathryn Bungartz, PhD, Professional Clinical Solutions Manager, QIAGEN Digital Insights
Learn how to use the Human Somatic Mutation Database (HSMD) as a clinical validation tool for clinical variant interpretation. In addition, this talk will show you how HSMD helps you gain genetic insights into specific cancer types and stay up-to-date with the latest treatment and clinical trial options.
Speaker: Iman Bhattacharya, Senior Global Product Marketing Manager, QIAGEN Digital Insights
North America Session
Learn about QIAGEN’s solution for cloud-based NGS secondary analysis and how to get started quickly with configurable pre-made workflows.
Speaker: Neha Jalan, PhD, Professional Services Solution Manager, QIAGEN Digital Insights
Learn how QIAGEN’s high-quality, deeply curated knowledge can help support and scale your variant interpretation. In addition, this talk will discuss the effects of co-occurring variants on prognosis and diagnosis and how to dentify evidence-based therapy options for cancer patients for whom there is no on-label therapy.
Speaker: Sheryl Elkin, PhD, Chief Scientific Officer, QIAGEN Digital Insights
Learn how to use the Human Somatic Mutation Database (HSMD) as a clinical validation tool for clinical variant interpretation. In addition, this talk will show you how HSMD helps you gain genetic insights into specific cancer types and stay up-to-date with the latest treatment and clinical trial options.
Speaker: Uma Thirumurthi, PhD, Associate Director of Global Product Management, QIAGEN Digital Insights
Claim your free database trials and software demos
All attendees of the 2023 Clinical Oncology Summit are eligible to request free trials and demos of the featured solutions.
QCI Secondary Analysis
Cloud-based service for NGS secondary analysis (FASTQ to VCF)
QCI Interpret for Oncology
Clinical decision support for variant interpretation and reporting (VCF to report)
Human Somatic Mutation Database
Somatic database to better understand precise variant function and actionability